Bottom line
SHISX vs XLV: the short answer
SHISX (Blackrock Health Sciences Opportunities Portfolio) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
But SHISX is far broader, holding 155 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 1.16% — a difference of $108 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +5.5% for SHISX.
Updated Nov 19, 2026
SHISX vs XLV side by side
| SHISX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | BlackRock | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.16% | 0.08% |
| Annual cost per $10k | $116 | $8 |
| 10-yr cost on $10k (prospectus) | $1,409 | $103 |
| Max front load | — | None |
| 12b-1 fee | 0.25% | 0.02% |
| 1-yr return | +15.9% | +14.5% |
| 5-yr return (annualized) | +5.5% | +8.1% |
| 10-yr return (annualized) | +9.5% | +9.8% |
| Best quarter | +17.5% | +14.5% |
| Worst quarter | −11.5% | −12.7% |
| Net assets (fund) | $5.9B | $40.6B |
| Number of holdings | 155 | 65 |
| Portfolio turnover | 49% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHISX | XLV | Difference |
|---|---|---|---|
| 2025 | +15.9% | +14.5% | +1.4% |
| 2024 | +3.8% | +2.5% | +1.3% |
| 2023 | +3.5% | +2.0% | +1.5% |
| 2022 | −6.0% | −2.1% | −3.9% |
| 2021 | +11.7% | +25.9% | −14.2% |
| 2020 | +19.4% | +13.3% | +6.2% |
| 2019 | +25.3% | +20.7% | +4.6% |
| 2018 | +8.0% | +6.3% | +1.7% |
| 2017 | +24.8% | +21.7% | +3.1% |
| 2016 | −6.1% | −2.8% | −3.2% |
Source: Fund prospectus bar charts
Holdings overlap
17 of SHISX's top 25 holdings also appear in XLV's top 25.
| Holding | SHISX | XLV |
|---|---|---|
| Eli Lilly & Company | 12.29% | 16.51% |
| Johnson & Johnson | 8.77% | 10.64% |
| Unitedhealth Group Inc | 6.10% | 6.57% |
| Merck & Company Inc | 4.94% | 5.52% |
| Gilead Sciences Inc | 4.19% | 2.73% |
| Abbvie Inc | 3.94% | 7.74% |
| Amgen Inc | 3.37% | 3.40% |
| Thermo Fisher Scientific Inc | 3.02% | 3.24% |
| Vertex Pharmaceuticals Inc | 2.74% | 2.19% |
| Pfizer Inc | 2.61% | 2.39% |
| Danaher Corp | 2.00% | 2.09% |
| Abbott Laboratories | 1.97% | 2.75% |
| Intuitive Surgical Inc | 1.95% | 2.45% |
| Boston Scientific Corp | 1.59% | 1.10% |
| Elevance Health Inc | 1.56% | 1.46% |
Source: SEC Form N-PORT
SHISX top 10
- Eli Lilly & Company — 12.29%
- Johnson & Johnson — 8.77%
- Unitedhealth Group Inc — 6.10%
- Merck & Company Inc — 4.94%
- Gilead Sciences Inc — 4.19%
- Abbvie Inc — 3.94%
- Amgen Inc — 3.37%
- Thermo Fisher Scientific Inc — 3.02%
- Vertex Pharmaceuticals Inc — 2.74%
- Pfizer Inc — 2.61%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between SHISX and XLV?
Which is cheaper, SHISX or XLV?
Should I own both SHISX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.